Overview

Molecular Imaging of Plaque Vulnerability

Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
0
Participant gender:
All
Summary
Accumulating data in the literature suggests that radiolabeled-choline (18F-choline) is a sensitive molecular tracer for PET imaging that is taken up in activated cells and, as such, is able to identify active inflammatory sites. The investigators hypothesize that 18F-choline is also highly taken up in vulnerable plaques in comparison to the stable ones.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Maastricht University Medical Center
Collaborator:
Center for Translational Molecular Medicine
Treatments:
Choline
Criteria
Inclusion Criteria:

- Patients known with symptomatic carotid artery stenosis (≥2 mm carotid plaque on
duplex ultrasound), who are scheduled in the clinical setting to undergo a carotid
endarterectomy or who are referred to conservative therapy;

- Age 18 years and older (no maximum age);

- Informed consent by signing informed consent form regarding this study.

Exclusion Criteria:

- Dementia, pregnancy, nursing mothers;

- Serious neurological deficits at symptomatic side (hemi paralysis, complete aphasia);

- Severe heart failure NYHA III-IV and severe pulmonary dysfunction dependent on oxygen
supply;

- Patients with contra-indications for MRI (ferromagnetic implants like pacemakers or
other electronic implants, metallic splinters in the eyes, vascular clips,
claustrophobia, etc.).